Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “A new approach towards a universal influenza vaccine: clinical update of OVX836”.
Author Archives: piomat
Immunotherapies & Innovation for Infectious Diseases (I4ID)
Lyon – Oral PresentationDelphine Guyon-Gellin, Chief of Business Development of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “A new approach towards a universal influenza vaccine: clinical update of OVX836”.
6th International Conference on Vaccine R&D
Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled “OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial”.
OSIVAX appoints Dr. W. Ripley Ballou (M.D) as member of its Clinical Advisory Board
Rip Ballou’s appointment will strengthen OSIVAX’s ambition to develop a pipeline of disruptive vaccines against infectious diseases. Lyon, France – September 22, 2021 – OSIVAX, a biopharmaceutical company focused on the development of “universal” vaccines against mutating viruses, including influenza and coronaviruses, announced today the appointment of Dr. Ripley Ballou (MD) as member of its Clinical …
Covid : Osivax, cette biotech lyonnaise à la recherche du “vaccin universel”
Companies to watch: Osivax
Can Covid-19 Vaccines Keep up with an Evolving Virus?
Osivax announces Last Subject Last Visit completed in Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate
Osivax announces Last Subject Last Visit completed in Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate — Full immunogenicity and safety results expected for early 2021 –Lyon, France – September 10, 2020 –Osivax announced today that the Last Subject’s Last Visit (LSLV) occurred in the Phase 2a clinical trial of OVX836 universal Influenza …
French biotech gets funding for universal flu and coronavirus vaccines
Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines
Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines — Company Secures EUR 17.5M from European Innovation Council and EUR 15.1M from Bpifrance as part of PSCP Covid-19 —Lyon, France – July 08, 2020 – Osivax announced today that it has received over EUR 30M in public funding from …